Merck announced Wednesday that the FDA OK'd RECARBIO, a combination of imipenem, cilastatin and relebactam in a 1.25g injection formulation.
The drug is intended to treat patients 18 and older for complicated urinary tract infection, or cUTI — including pyelonephritis — caused by some susceptible gram-negative microorganisms and for which there is limited or no alternative treatment options.
The antibacterial medication is also indicated to treat complicated intra-abdominal infections.
"RECARBRIO offers an additional treatment option for patients with cIAI and cUTI who have limited and, in some cases, no alternative therapeutic options," Keith Kaye, a principal investigator of the clinical program that evaluated the antibiotic combo, said in a statement.
Merck shares were trading higher by 0.42% at $81.93 at the time of publication Wednesday.
Merck Strikes 3M Deal For Privately Held Tilos Therapeutics
Washington Worries Trigger Bearish Merck Options Trades
See more from Benzinga
- The Week Ahead In Biotech: Johnson & Johnson Kickstarts Big Pharma Earnings
- Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug
- The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.